Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-FPD vs R-MAD in PCNSL
NCT04083066Phase 4Unknown
- Start
- Sep 2019
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fotemustine and pemetrexed in primary central nervous system lymphoma (PCNSL) (2 arms). Primary endpoints: Objective Response Rate at 24 months and Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
fotemustinepemetrexed
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04083066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083066.